[HTML][HTML] Interrupting endocrine therapy to attempt pregnancy after breast cancer
…, C Saura, C Shimizu, AB Sætersdal… - New England journal …, 2023 - Mass Medical Soc
Background Prospective data on the risk of recurrence among women with hormone
receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt …
receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt …
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer
…, L Vindi, HH Sommer, AB Sætersdal… - Journal of Clinical …, 2014 - ascopubs.org
Purpose The presence of disseminated tumor cells (DTCs) in bone marrow (BM) predicts
survival in early breast cancer. This study explores the use of DTCs for identification of patients …
survival in early breast cancer. This study explores the use of DTCs for identification of patients …
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
…, MK Tuxen, EH Jakobsen, A Saetersdal… - Breast cancer research …, 2011 - Springer
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown both anti-proliferative
and anti-tumoral activity in breast cancer. This study was designed to determine …
and anti-tumoral activity in breast cancer. This study was designed to determine …
[HTML][HTML] Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
…, M Colleoni, C Saura, C Shimizu, AB Sætersdal… - The Breast, 2021 - Elsevier
Background Premenopausal women with early hormone-receptor positive (HR+) breast
cancer receive 5–10 years of adjuvant endocrine therapy (ET) during which pregnancy is …
cancer receive 5–10 years of adjuvant endocrine therapy (ET) during which pregnancy is …
Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors
Targeted therapy for patients with HER 2‐positive ( HER 2+) breast cancer has improved
overall survival, but many patients still suffer relapse and death from the disease. Intratumor …
overall survival, but many patients still suffer relapse and death from the disease. Intratumor …
Radiation-induced effects on gene expression: an in vivo study on breast cancer
…, C Frøyland, HBK Landmark, AB Sætersdal… - Radiotherapy and …, 2006 - Elsevier
BACKGROUND AND PURPOSE: Breast cancer is diagnosed worldwide in approximately
one million women annually and radiation therapy is an integral part of treatment. The …
one million women annually and radiation therapy is an integral part of treatment. The …
Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
…, F Busato, J Tost, AB Sætersdal… - … journal of cancer, 2014 - Wiley Online Library
Radiotherapy (RT) is a central treatment modality for breast cancer patients. The purpose of
our study was to investigate the DNA methylation changes in tumors following RT, and to …
our study was to investigate the DNA methylation changes in tumors following RT, and to …
Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE …
…, M Colleoni, C Saura, C Shimizu, A Saetersdal… - Cancer Research, 2023 - AACR
Background: Pregnancy after breast cancer (BC) is of substantial importance for many
young women at diagnosis and during follow-up. BC treatment including standard endocrine …
young women at diagnosis and during follow-up. BC treatment including standard endocrine …
Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant …
…, E Bifulco, JT Kvaløy, AB Sætersdal… - Molecular …, 2021 - Wiley Online Library
Low steady‐state levels of active tamoxifen metabolites have been associated with inferior
treatment outcomes. In this retrospective analysis of 406 estrogen receptor‐positive breast …
treatment outcomes. In this retrospective analysis of 406 estrogen receptor‐positive breast …
Abstract OT1-01-06: POSITIVE: a study evaluating pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with …
Background Young patients with breast cancer (BC) are often diagnosed with the disease
before completing their families. The best available retrospective evidence suggests that …
before completing their families. The best available retrospective evidence suggests that …